Upcoming Events.
Immutep to Host Key Opinion Leader Call on Novel Immuno-Oncology Therapy (eftilagimod alpha) in Metastatic Breast Cancer and Other Settings
The call will feature overview presentations by KOLs: Dr. Luc Dirix, MD PhD, from the AZ Sint-Augustinus Hospital in Antwerp, Belgium, and Prof. Salah-Eddin Al-Batran, MD, from the Institute of Clinical Research in Frankfurt, Germany. They will discuss their clinical experience with eftilagimod alpha in AIPAC (metastatic breast cancer) and INSIGHT (exploratory investigator-initiated trial) as well as the current treatment landscape and unmet medical needs, specifically in HER2-negative / HR positive metastatic breast cancer.
Time: Wednesday, June 26 at 11.00am EDT / 8.00am PDT (Thursday, June 27 at 1.00am AEST)
ESMO 2019 Congress
Representatives of the company will be attending the conference.
Venue: www.firabarcelona.com
Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
34th Annual Meeting SITC 2019
The company will have presentations at the conference and representatives will be attending.
Venue: https://www.nationalharbor.com/gaylord-national/
Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA
Past Events.
Immutep to Host Key Opinion Leader Call on Novel Immuno-Oncology Therapy (eftilagimod alpha) in Metastatic Breast Cancer and Other Settings
The call will feature overview presentations by KOLs: Dr. Luc Dirix, MD PhD, from the AZ Sint-Augustinus Hospital in Antwerp, Belgium, and Prof. Salah-Eddin Al-Batran, MD, from the Institute of Clinical Research in Frankfurt, Germany. They will discuss their clinical experience with eftilagimod alpha in AIPAC (metastatic breast cancer) and INSIGHT (exploratory investigator-initiated trial) as well as the current treatment landscape and unmet medical needs, specifically in HER2-negative / HR positive metastatic breast cancer.
Time: Wednesday, June 26 at 11.00am EDT / 8.00am PDT (Thursday, June 27 at 1.00am AEST)
World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
Conference Day 2: Friday 17th May 2019/ 11.25.a.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials
Venue: Business Design Centre, London, UK
New York Academy of Sciences, Frontiers in Cancer Immunotherapy
Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.
Venue: The New York Academy of Sciences, New York, New York, USA
ESMO Breast Cancer Congress 2019
Venue: Maritim Hotel Berlin, Stauffenbergstrasse 26, 10785 Berlin, Germany
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
The webcast was hosted by Dr. Triebel, Marc Voigt, CEO and Christian Mueller, Director of Clinical Development.
Register: Interested investors can register via a link to the recorded webcast at the following link.
Listen to the related webcast: Update on Eftilagimod Alpha (IMP321)
American Association for Cancer Research (AACR) Annual Meeting 2019
Representatives of the company will be attending the conference
Venue: Georgia World Congress Center, Atlanta, Georgia, USA
Immutep to Present IMP761 Preclinical Results in Global Webcast
Speakers: Chief Scientific Officer & Chief Medical Officer, Dr. Frederic Triebel and Executive Director and Chief Executive Officer (CEO) Marc Voigt
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, USA
14th Congress of ECCO - Inflammatory Bowel Diseases 2019, Copenhagen, Denmark
Mathieu Angin, Phd, Immutep Research Scientist presents an abstract:
“IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases.”
Session name: DOP Session 1: Advances in IBD pathophysiology
Session date: 07 March 2019
Session time: 17:30 - 18:30
Session hall: C1 M1
Venue: Bella Center, Center Blvd. 5, 2300 Copenhagen, Denmark
World Immunotherapy Congress USA 2019
Day 2 – Tuesday 5th March/ 3.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients
Venue: Grand Hyatt, San Diego, USA
Emergence 2019 Conference - Sydney
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Venue: SYDNEY InterContinental, 170 Macquarie Street, Sydney; NSW; Australia
Emergence 2019 Conference - Brisbane
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Venue: BRISBANE Hilton, 190 Elizabeth Street, Brisbane City; QLD; Australia
37th Annual J.P. Morgan Health Care Investor Conference
Venue: San Francisco, California, USA
4th Annual ICI Europe Summit
conference day 1/ 02.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab
Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany
Macquarie Life Sciences Corporate Day - Sydney
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Macquarie Office - Sydney, Australia
33rd Annual Meeting SITC 2018
The company will have presentations at the conference and representatives will be attending.
Venue: Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA
World Immunotherapy Congress 2018
day 2/ 2:55 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab
Venue: Basel Congress Center, Basel, Switzerland
Australian Biotech Invest & Partnering 2018
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia
15th International Congress of the Society for Melanoma Research
Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:
"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."
Venue: Manchester Central Convention Complex, Manchester, United Kingdom
ESMO 2018 Congress
Representatives of the company will be attending the conference.
Venue: Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.
Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”
Download "Ladenburg 2018 HC Conference Immutep Presentation"
BioCentury 25th Annual NewsMakers - Biotech Industry Conference
Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day.
Venue: Millenium Broadway Hotel & Conference Center, NY, USA
Press release: click here
Download "Newsmaker Immutep Corporate Presentation"
Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018
BIONNALE 2018, Berlin, Germany
- the largest networking event for life sciences and healthcare industries in the German capital region -
Venue: Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
3rd Annual Advances in Immuno-Oncology Congress, 24 - 25 May 2018, London, UK
Frédéric Triebel speaks on the subject:
“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”
13th Annual Advanced Therapy and Regenerative Medicine Congress 2018, 16 – 18 May, London, UK
Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”
Deutsche Biotechnologietage 2018/ German Biotech Days 2018
Venue: bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany
American Association for Cancer Research (AACR) Annual Meeting 2018
Venue: McCormick Place, Chicago, IL, USA
The MicroCap Conference
Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th
Venue: Essex House, New York, NY, USA